172 related articles for article (PubMed ID: 36714137)
1. Comparison of hepatotoxicity of tegoprazan, a novel potassium-competitive acid blocker, with proton pump inhibitors using real-world data: A nationwide cohort study.
Kim MG; Im YJ; Lee JH; Kim EY; Yeom SW; Kim JS
Front Med (Lausanne); 2022; 9():1076356. PubMed ID: 36714137
[TBL] [Abstract][Full Text] [Related]
2. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Li XQ; Andersson TB; Ahlström M; Weidolf L
Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
[TBL] [Abstract][Full Text] [Related]
3. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
Caro JJ; Salas M; Ward A
Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD
Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560
[TBL] [Abstract][Full Text] [Related]
5. Acid-suppressive drugs: A systematic review and network meta-analysis of their nocturnal acid-inhibitory effect.
Zou S; Ouyang M; Cheng Q; Shi X; Sun M
Pharmacotherapy; 2024 Feb; 44(2):171-183. PubMed ID: 38049205
[TBL] [Abstract][Full Text] [Related]
6. Proton pump inhibitor therapy and risk of knee replacement surgery: a general population-based cohort study.
Zeng C; Neogi T; Chan AT; Wei J; Misra D; Lu N; Choi HK; Lei G; Zhang Y
Osteoarthritis Cartilage; 2022 Apr; 30(4):559-569. PubMed ID: 35031493
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole.
Abed MN; Alassaf FA; Jasim MHM; Alfahad M; Qazzaz ME
Pharmacology; 2020; 105(11-12):645-651. PubMed ID: 32289807
[TBL] [Abstract][Full Text] [Related]
8. Time-Varying Use of Proton Pump Inhibitors and Cognitive Impairment and Dementia: A Real-World Analysis from Germany.
Ahn N; Wawro N; Baumeister SE; Nolde M; Gerlach R; Tauscher M; Günter A; Güntner F; Rückert-Eheberg IM; Meisinger C; Linseisen J
Drugs Aging; 2023 Jul; 40(7):653-663. PubMed ID: 37178361
[TBL] [Abstract][Full Text] [Related]
9. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
[TBL] [Abstract][Full Text] [Related]
10. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
de Korwin JD; Ducrotté P; Vallot T
Presse Med; 2004 Jun; 33(11):746-54. PubMed ID: 15257232
[TBL] [Abstract][Full Text] [Related]
11. Stereoselective disposition of proton pump inhibitors.
Andersson T; Weidolf L
Clin Drug Investig; 2008; 28(5):263-79. PubMed ID: 18407713
[TBL] [Abstract][Full Text] [Related]
12. Proton Pump Inhibitors and Bone Health: An Update Narrative Review.
Lespessailles E; Toumi H
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142643
[TBL] [Abstract][Full Text] [Related]
13. Qualimetric analysis of proton pump inhibitors in Ukraine.
Makarenko OV; Karimova MM; Masheiko AM; Onul NM
Wiad Lek; 2019; 72(9 cz 2):1769-1773. PubMed ID: 31622264
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
Welage LS; Berardi RR
J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
[TBL] [Abstract][Full Text] [Related]
15. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Röhss K; Lind T; Wilder-Smith C
Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
[TBL] [Abstract][Full Text] [Related]
16. Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients.
Pilotto A; Franceschi M; Leandro G; Scarcelli C; D'Ambrosio LP; Paris F; Annese V; Seripa D; Andriulli A; Di Mario F
World J Gastroenterol; 2007 Sep; 13(33):4467-72. PubMed ID: 17724802
[TBL] [Abstract][Full Text] [Related]
17. Associations of proton pump inhibitors and hospitalization due to hyponatremia: A population-based case-control study.
Falhammar H; Lindh JD; Calissendorff J; Skov J; Nathanson D; Mannheimer B
Eur J Intern Med; 2019 Jan; 59():65-69. PubMed ID: 30154038
[TBL] [Abstract][Full Text] [Related]
18. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs.
Edwards SJ; Lind T; Lundell L
Aliment Pharmacol Ther; 2006 Sep; 24(5):743-50. PubMed ID: 16918878
[TBL] [Abstract][Full Text] [Related]
19. Effects of Tegoprazan, a Novel Potassium-Competitive Acid Blocker, on Rat Models of Gastric Acid-Related Disease.
Kim DK; Lee KH; Kim SJ; Kim SJ; Lee SJ; Park CH; Kim BT; Song GS; Moon BS; Ryu SY
J Pharmacol Exp Ther; 2019 Jun; 369(3):318-327. PubMed ID: 30894456
[TBL] [Abstract][Full Text] [Related]
20. Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality.
Kromer W
Scand J Gastroenterol Suppl; 2001; (234):3-9. PubMed ID: 11768559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
